The Lancet HIV in conversation with

Kelly Dooley and Gavin Churchyard on TB prevention in people with HIV

June 03, 2020 The Lancet HIV

Kelly Dooley (Johns Hopkins University, USA) and Gavin Churchyard (Aurum Institute, South Africa) discuss their trial on tuberculosis prevention in people with HIV taking dolutegravir-based antiretroviral therapy with Deputy Editor Philippa Harris. 

Pre-roll ad for multimedia hub, voiced and produced by Gavin

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv